Soria JC - Search Results

1

T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.

Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, Rugo HS, Cohen RB, O'Neil BH, Mehnert JM, Lopez J, Doi T, van Brummelen EMJ, Cristescu R, Yang P, Emancipator K, Stein K, Ayers M, Joe AK, Lunceford JK. Ott PA, et al. Among authors: soria jc. J Clin Oncol. 2019 Feb 1;37(4):318-327. doi: 10.1200/JCO.2018.78.2276. Epub 2018 Dec 13. J Clin Oncol. 2019. PMID: 30557521 Clinical Trial.

2

Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?

Soria JC, Brisgand D, Le Chevalier T. Soria JC, et al. Ann Oncol. 2001 Dec;12(12):1667-70. doi: 10.1023/a:1013574413217. Ann Oncol. 2001. PMID: 11843242 Free article. Clinical Trial.

3

hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer.

Wang L, Soria JC, Kemp BL, Liu DD, Mao L, Khuri FR. Wang L, et al. Among authors: soria jc. Clin Cancer Res. 2002 Sep;8(9):2883-9. Clin Cancer Res. 2002. PMID: 12231532

4

Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer.

Soria JC, Moon C, Kemp BL, Liu DD, Feng L, Tang X, Chang YS, Mao L, Khuri FR. Soria JC, et al. Clin Cancer Res. 2003 May;9(5):1785-91. Clin Cancer Res. 2003. PMID: 12738735

5

Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers.

Lu C, Soria JC, Tang X, Xu XC, Wang L, Mao L, Lotan R, Kemp B, Bekele BN, Feng L, Hong WK, Khuri FR. Lu C, et al. Among authors: soria jc. J Clin Oncol. 2004 Nov 15;22(22):4575-83. doi: 10.1200/JCO.2004.01.091. J Clin Oncol. 2004. PMID: 15542809

6

Catalytic subunit of human telomerase reverse transcriptase is an independent predictor of survival in patients undergoing curative resection of hepatic colorectal metastases: a multicenter analysis.

Dômont J, Pawlik TM, Boige V, Rose M, Weber JC, Hoff PM, Brown TD, Zorzi D, Morat L, Pignon JP, Rashid A, Jaeck D, Sabatier L, Elias D, Tursz T, Soria JC, Vauthey JN. Dômont J, et al. Among authors: soria jc. J Clin Oncol. 2005 May 1;23(13):3086-93. doi: 10.1200/JCO.2005.06.944. J Clin Oncol. 2005. PMID: 15860868

7

Adjuvant chemotherapy in early-stage non-small cell lung cancer.

Dômont J, Soria JC, Le Chevalier T. Dômont J, et al. Among authors: soria jc. Semin Oncol. 2005 Jun;32(3):279-83. doi: 10.1053/j.seminoncol.2005.02.018. Semin Oncol. 2005. PMID: 15988682 Review.

8

QTc monitoring during a phase I study: experience with SR271425.

Soria JC, Dieras V, Girre V, Yovine A, Mialaret K, Armand JP. Soria JC, et al. Am J Clin Oncol. 2007 Apr;30(2):106-12. doi: 10.1097/01.coc.0000255604.32888.b5. Am J Clin Oncol. 2007. PMID: 17414458 Clinical Trial.

9

Are RAS mutations predictive markers of resistance to standard chemotherapy?

Loriot Y, Mordant P, Deutsch E, Olaussen KA, Soria JC. Loriot Y, et al. Among authors: soria jc. Nat Rev Clin Oncol. 2009 Sep;6(9):528-34. doi: 10.1038/nrclinonc.2009.106. Epub 2009 Jul 14. Nat Rev Clin Oncol. 2009. PMID: 19597509 Review.

10

Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer.

Soria JC, Smit E, Khayat D, Besse B, Yang X, Hsu CP, Reese D, Wiezorek J, Blackhall F. Soria JC, et al. J Clin Oncol. 2010 Mar 20;28(9):1527-33. doi: 10.1200/JCO.2009.25.4847. Epub 2010 Feb 16. J Clin Oncol. 2010. PMID: 20159815 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

732 results

Search Page